Relay Therapeutics, Inc. (RLAY) Dividend History

Relay Therapeutics, Inc. (RLAY) is a biotechnology company focused on designing and developing precision medicines by integrating advanced computational and experimental methods. The company aims to target dynamic proteins involved in disease processes, particularly in oncology, to create innovative therapies with improved efficacy and safety profiles.

399 Binney Street, Cambridge, MA, 02139
Phone: 617-370-8837
Website: https://www.relaytx.com

Dividend History

Relay Therapeutics, Inc. currently does not pay dividends

Company News

  • Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

    Kymera Therapeutics announced the appointment of Brian Adams as Chief Legal Officer, succeeding Ellen Chiniara who is retiring. Adams brings nearly two decades of legal leadership experience in life sciences and will oversee legal, governance, and intellectual property functions.

    GlobeNewswire Inc.
    Featured Companies: KYMR
  • Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders

    The article discusses the rapid adoption of artificial intelligence (AI) in the healthcare industry, with several tech and biotech companies making significant strides. It highlights the potential of AI to transform various aspects of healthcare, including early disease detection and intelligent therapeutics.

    Benzinga
    Featured Companies: ATR BFLY
  • Why Relay Therapeutics Plummeted by Nearly 14% Today

    Relay Therapeutics, a biotech company developing oncology treatments, announced a secondary share offering of 28.6 million shares at $7 per share, which is seen as highly dilutive to existing shareholders. The stock fell nearly 14% in response, while the broader market gained over 1%.

    The Motley Fool
  • Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates

    Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 11.43% and 2,905.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: BCRX
Page data last updated 09/07/2025 04:11:36 UTC